Zydus Introduces Zyrifa Biosimilar to Ease Cancer Bone Treatment

Zydus Lifesciences Ltd. has launched Zyrifa, a 120 mg subcutaneous biosimilar of the monoclonal antibody Denosumab.

The new product increases the number of cancer patients who can receive advanced treatment of bone-care which is cheaper alternative and helps control more severe bone complications that happen when cancer spreads to the bones.

The presence of bone metastases are some of the most painful and debilitating outcomes of advanced cancers. They impact 70 percent or more of those with late-stage breast or prostate cancer, and frequently cause sudden pain, fractures, and a rapid deterioration in the daily mobility of the patient. These complications interfere with the treatment and impose a significant burden on the quality of life.

Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future

Zyrifa can be used in patients whose bone metastases are due to a wide variety of solid tumors, such as breast, prostate, lung, kidney, thyroid, and head-and-neck tumours. This Denosumab biosimilar will help lower the cost burden on cancer patients who will require extended therapy to prevent skeletal-related events, as cost of cancer-care starts to climb.

Managing Director of Zydus Lifesciences Dr. Sharvil P. Patel stated: Zydus Lifesciences aims to provide greater access and affordability to cancer patients in need of critical care with Denosumab 120 mg SC. This drug will assist the patients to continue living with dignity as they fight their illness.

Zyrifa will be marketed at an MRP of 12,495, which will enhance Zydus to have a robust portfolio of biosimilar oncology drugs. The company expects to increase access to treatment throughout India as the demand of bone-care therapies that are reliable and affordable has been increasing.